山东医药2012，Vol.52Issue(34)：1-4,4.
慢性淋巴细胞白血病患者外周血p53基因突变观察
p53 gene mutation in chronic lymphocytic leukemia patients' peripheral blood
摘要
Abstract
Objective To investigate the mutation of p53 and its clinical significance in peripheral blood of patients with chronic lymphocytic leukemia ( CLL). Methods p53 gene mutations were detected by polymerase chain reaction (PCR) and subsequent sequencing in peripheral blood of 80 CLL patients and 10 healthy controls. FC regimens (fludara-bine 25 mg/m2, cyclophosphamide 250 mg/m2, intravenous infusion for 3 days) were repeated for 2 to 6 cycles at four weeks intervals were administrated in 25 patients. Results Among 80 patients, 12 (15.0%) cases had p53 mutations, including 11 cases of missense mutations and 1 case of nonsense mutation. No insertions or insertions were detected. Mutations were discovered in exon 5 to 9, including 2 cases of exon 5, 3 cases of exon 6, 1 case of exon 7, 5 cases of exon 8 and 1 case of exon 9. No mutations were detected in 10 healthy controlsor the remaining exons in CLL patients (all P < 0.05 ). Patients with p53 mutations displayed higher incidence of advanced stage, p53 deletions, and unmutated IgVH ( all P < 0.05 ) . In 25 patients treated with FC regimens, 5 cases achieved CR and 11 cases obtained PR (OR, overall response 64.0% ). Patients with p53 mutations showed lower incidence of overall response than patients without mutations (14. 3% vs 83. 3% , P <0.05). Conclusions p53 mutations occur in peripheral blood of patients with CLL. Our data confirm a role for p53 mutations as an important prognostic indicator in CLL.关键词
p53基因/基因突变/慢性淋巴细胞白血病Key words
p53 gene/ mutation/ chronic lymphocytic leukemia分类
医药卫生引用本文复制引用
朱家斌,周立涛,王晓炜,徐卫,于亮,李建勇..慢性淋巴细胞白血病患者外周血p53基因突变观察[J].山东医药,2012,52(34):1-4,4.基金项目
国家自然科学基金资助项目(81170489) （81170489）
江苏省自然科学基金资助项目(BK2010287). （BK2010287）
